



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No.: 107223.167 (US2))

Applicant(s): Sanghvi, et al.

Serial No.: 10/630,239

Examiner: Not Yet Assigned

Filed: July 30, 2003

Group Art Unit: Not Yet Assigned

For: SUSTAINED RELEASE FORMULATIONS OF METFORMIN


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria VA. 22313-1450 on the date set forth below.

12-17-03

Date


James F. Coughlan

TRANSMITTAL LETTER

Commissioner:


Enclosed for filing in the above-identified application are the following documents:

- 1.) Information Disclosure Statement, including 40 references;
- 2.) Form PTO-1449; and
- 3.) Return Postcard.

Please charge any deficiency or credit any overpayment in connection with this matter to Deposit account No. 08-0219.

Respectfully submitted,

Dated: 12/17/03


Emily R. Whelan
Registration No. 50,391

Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6567
Fax: (617) 526-5000



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No.: 107223.167 (US2))

Applicant(s): Sanghvi, et al.

Serial No.: 10/630,239

Examiner: Not Yet Assigned

Filed: July 30, 2003

Group Art Unit: Not Yet Assigned

For: SUSTAINED RELEASE FORMULATIONS OF METFORMIN


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date set forth below.

12-17-03

Date


James F. Coughlan

INFORMATION DISCLOSURE STATEMENT

Commissioner:

Applicant and his attorney are aware of the following publications and information listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submits these publications for the Examiner's consideration.

Pursuant to 37 C.F.R. §1.97, Applicant hereby makes of record the documents listed on the attached Form PTO-1449.

It is respectfully requested that the information above be expressly considered during the prosecution of this application and that the publications be made of record therein and appear among the "References Cited" on any patent to issue therefrom. In this regard, it is requested that the Examiner initial and return a copy of the enclosed Form PTO-1449 with the next Patent Office Communication.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

U.S.S.N. 10/630,239
Sanghvi, et al.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits and is therefore submitted as both timely and proper; therefore, no fees are believed to be due.


The Commissioner, however, is hereby authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. 08-0219.

Respectfully submitted,

Date: 12/17/03


Emily R. Whelan
Registration No. 50,391

Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6567
Fax: (617) 526-5000



Subt. Form PTO-1449				Docket Number 107223.167 US2		Application Number 10/630,239	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Sanghvi, et al.			
				Filing Date July 30, 2003		Group Art Unit Not yet assigned	
Sheet	1	OF	2				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,128,143	7/7/92	Baichwal, et al.	424	464	
	5,135,757	8/4/92	Baichwal, et al.	424	465	
	5,455,046	8/29/95	Kataumi, et al.	74	527	
	5,512,297	4/30/96	Baichwal	424	451	
	5,554,387	9/10/96	Baichwal	424	488	
	5,399,358	3/21/95	Baichwal, et al.	424	464	
	5,399,359	3/21/95	Baichwal	424	464	
	5,670,168	9/23/97	Baichwal, et al.	424	464	
	4,828,836	5/9/89	Elger, et al.	424	419	
	6,340,475	1/22/02	Shell, et al.	424	469	
	4,351,825	9/28/82	Sothmann, et al.	424	19	
	5,055,306	10/8/91	Barry, et al.	424	482	
	5,330,767	7/19/94	Yamamoto, et al.	424	497	
	5,611,971	3/18/97	Maedera, et al.	264	4.1	
	5,631,021	5/20/97	Okada, et al.	424	451	
	5,651,990	7/29/97	Takada, et al.	424	497	
	3,629,393	12/21/97	Nakamoto, et al.	424	22	

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	99/47128	9/23/99	WO				
	97/17975	5/22/97	WO				
	44 32 757	3/21/96	DE			YES	
	0 749 751	12/27/96	EP				
	0 580 428	10/1/97	EP				
	0 709 085	5/1/96	EP				
	0 531 497	8/13/97	EP				
	0 251 459	7/8/92	EP				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

Subt. Form PTO-1449				Docket Number 107223.167 US2	Application Number 10/630,239
<p align="center">INFORMATION DISCLOSURE IN AN APPLICATION</p> <p align="center">Use several sheets if necessary)</p>				Applicant Sanghvi, et al.	
				Filing Date July 30, 2003	Group Art Unit Not yet assigned
Sheet 1	2	OF	2		



A1	Campbell, et al., "A Clinical Evaluation of a Delayed Release Preparation of Metformin," <i>J Int Med Res</i> , Vol. 1, pp.551-556 (1973)
A2	Pentikainen, "Bioavailability of Metformin. Comparison of solution, rapidly dissolving tablet, and three sustained release products," <i>Int J Clin Pharmacol, Ther and Toxicol</i> , Vol. 4, pp. 213-220 (1986)
A3	Abdallah, et al., "Preparation and evaluation of metformin hydrochloride controlled-release tablets," <i>S.T.P. Pharma</i> , Vol. 4(1), pp. 15-20 (1988)
A4	Karttunen, et al., "The Pharmacokinetics of metformin: a comparison of the properties of a rapid-release and sustained-release preparation," <i>Int J Clin Pharmacol, Ther and Toxicol</i> , Vol. 21(1), pp. 31-36 (1983)
A5	Mosby's GenRx, "Drug Names – Metformin Hydrochloride (3204) Categories, Brand Names, Formularies & Cost of Therapy," (1998) pp.1-17
A6	Saleh, "Tablets produced under licence Do they have the same dissolution characteristics and drug content uniformity as the original ones? Example: metformin hydrochloride sustained-release tablets," <i>S.T.P. Pharma</i> , Vol. 6(8), pp. 598-603 (1990)
A7	Grdinic, et al., "Comparison of in-vitro release and renal elimination of 1-butylbiguanide from times-release oral antidiabetic preparations," <i>Acta Pharm. Jugoslav.</i> , Vol. 29, pp. 215-221 (1979)
A8	Dimitrijevic, et al., "Electro-Responsive Release From A Chondroitin Sulphate Hydrogel," <i>J. Pharm. Pharmacol.</i> , Vol. 47, pp. 1058 (1995)
A9	Karttunen, "The Influence of Pharmaceutical Formulation on the Gastrointestinal Side Effects of Metformin," <i>Scandinavian Society for the Study of Diabetes</i> , 15 th Annual Meeting, Norway (1980)
A10	Noel, "Kinetic Study of Normal and Sustained Release Dosage Forms of Metformin in Normal Subjects," <i>Research and Clinical Forums</i> , Vol. 1(4), pp. 35-50 (1979)
A11	Noel, "Kinetic Study of Normal and Sustained Release Dosage Forms of Metformin in Normal Subjects," <i>Journal of International Biomedical Information and Data</i> , Vol. 1(1), pp. 9-20 (1980)
A12	Bristol-Myers Squibb, "Glucophage XR (Metformin HCl extended-release) Tablets, Rx," <i>FDA Website</i> , (Posted October 20, 2000)
A13	"Glucophage Retard," <i>The Rote Liste</i> (1993)
A14	Araman, et al., "In Vivo-In Vitro Correlation of Prolinged Release Metformin HCL Tablets Prepared with Coating Materials," <i>Supplement F, Supplement to Pharmaceutisch Weekblad Scientific Edition</i> , 1 st European Congress of Pharmaceutical Science, Vol. 14(5) (1992)
A15	Stanforth, "Synergistically Interacting Heterodisperse Polysaccharides – Function in Achieving Controllable Drug Delivery," <i>American Chemical Society</i> (1993)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	